Smyth, Lillian M.
Monson, Kelsey R.
Jhaveri, Komal
Drilon, Alexander
Li, Bob T.
Abida, Wassim
Iyer, Gopa
Gerecitano, John F.
Gounder, Mrinal
Harding, James J.
Voss, Martin H.
Makker, Vicky
Ho, Alan L.
Razavi, Pedram
Iasonos, Alexia
Bialer, Philip
Lacouture, Mario E.
Teitcher, Jerrold B.
Erinjeri, Joseph P.
Katabi, Nora
Fury, Matthew G.
Hyman, David M.
Article History
Received: 21 December 2016
Accepted: 23 February 2017
First Online: 9 March 2017
Compliance with ethical standards
:
: M.F., K.J., A.H., M.L, and M.V. have served on advisory boards and/or consulted for Novartis.LMS: Advisory- Genentech, Research - AstraZeneca.KJ: Consulting/Advisory - Novartis.DH: Consulting - Chugai, CytomX, Atara, Research/Grants-AstraZeneca, PUMA, LOXO.AH: Advisory/ Speaker- Novartis.MV: Consulting- Novartis, Exelixis, Pfizer, Alexion, Research- BMS, Genentech.No potential conflict of interest was disclosed by the other authors.
: Funding was received from Novartis Pharmaceuticals. Saiprasad Boddu, of Sai Life Sciences, performed the pharmacokinetic analyses.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.